Drug Profile
Albutegrin
Latest Information Update: 31 Oct 2005
Price :
$50
*
At a glance
- Originator Human Genome Sciences
- Class
- Mechanism of Action Osteoclast inhibitors; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bone disorders; Osteoporosis
Most Recent Events
- 31 Oct 2005 Discontinued - Preclinical for Bone disorders in USA (unspecified route)
- 31 Oct 2005 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)
- 30 Jul 2002 Preclinical trials in Bone disorders in USA (unspecified route)